GRI Bio, Inc.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving GRI Bio, Inc. now
Current reporting with the operating signal separated from the noise.
GRI Bio, Inc.: GRI Bio Announces Reverse Stock Split
Investors are testing whether GRI Bio, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.GRI Bio, Inc.: GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights
The story matters when it changes GRI Bio, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.GRI Bio, Inc. Reports Positive Interim Safety Results for GRI-0621 in Phase 2a Study for Idiopathic Pulmonary Fibrosis
The story matters when it changes GRI Bio, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: regulator filings, verified operating scope and liability disclosures.GRI Bio, Inc. Advances Global Patent Strategy with European Patent Grant for NKT Cell Modulator Innovation
The story matters when it changes GRI Bio, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Latest GRI filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
GRI Bio, Inc., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
No verified period-specific item in the current feed.
SEARCH Q1 COVERAGE →Second quarter
No verified period-specific item in the current feed.
SEARCH Q2 COVERAGE →Third quarter
No verified period-specific item in the current feed.
SEARCH Q3 COVERAGE →